

10/531504

JC13 Rec'd CT/PTO 13 APR 2005 #3

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John J. Renger, et al.

Int'l Appln.
No. : PCT/US03/32892

Int'l Date
Filed : 19 September 2003 (19/09/2003)

Serial No. : (To be assigned) Case No.: 21245YP

Filed : April 13, 2005

For : ENHANCEMENT OF SLEEP WITH T-TYPE CALCIUM
CHANNEL ANTAGONISTS

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT April 13, 2005
EXPRESS MAIL NO. EL 989 580 941 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Ron Schepin
DATE April 13, 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By J. Eric Thies

J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: April 13, 2005

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN**Application Number****Filing Date**

March 11, 2005

First Named Inventor

John J. Renger et al

Group Art Unit

Examiner Name

Attorney Docket Number

21245YP

U.S. PATENT DOCUMENTSExaminer
Initials*Cite
No.

U.S. Patent Document

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

133/04/6344 BC

FOREIGN PATENT DOCUMENTS

Examiner
Initials*Cite
No.

Foreign Patent Document

Office

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

WO 93/04047

Merck & Co., Inc.

03/04/1993

WO 01/02561

Neuromed Technologies, Inc.

01/11/2001

Examiner
Signature

Date
Considered

Substitute for form 1449B/PTO

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

107531504

Application Number**Filing Date**

March 11, 2005

First Named Inventor

John J. Renger et al

Group Art Unit

Examiner Name

Sheet

2

of

2

Attorney Docket Number

21245YP

[illegible]Examiner
Initials*

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Santi, C. et al. Differential Inhibition of T-Type Calcium Channels by Neuroleptics. Journal Neuroscience. 15 January 2002, vol. 22, No. 2, pages 396-403.

Massie, B.M. Mibefradil a T-Type Channel-Selective Calcium Antagonist: Clinical Trails in Chronic Stable Angina Pectoris. American Jouranal of Hypertension. April 1998, vol 11, No. 4, pages 95S-102S.

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003